, and the extent of protein O-GlcNAcylation, are upregulated in tumor tissue, and correlate with cancer progression. Here we compare the significance of O-GlcNAcylation in a panel of breast cancer cells of different phenotypes. We find a greater dependency on OGT among triple-negative breast cancer (TNBC) cell lines, which respond to OGT inhibition by undergoing cell cycle arrest and apoptosis. Searching for the cause of this response, we evaluate the changes in the proteome that occur after OGT inhibition or knock-down, employing a reverse-phase protein array (RPPA). We identify transcriptional repressor -hairy and enhancer of split-1 (HES1) -as a mediator of the OGT inhibition response in the TNBC cells. Inhibition of OGT as well as the loss of HES1 results in potent cytotoxicity and apoptosis. The study raises a possibility of using OGT inhibition to potentiate DNA damage in the TNBC cells.
www.nature.com/scientificreports www.nature.com/scientificreports/ forward: CGAGTGAACATTCCCATCACT, reverse: CCCAAAGGAGCACAGATGTT; PTEN forward: CGAACTGGTGTAATGATATGT, reverse: CATGAACTTGTCTTCCCGT.
The following antibodies from Cell Signaling Technology (Danvers, MA) were used: anti-OGT (#5368), anti-HES1 (#11988), anti-phospho-Ser235/236-S6 (#4858), anti-γ-H2AX (#9718), anti-PARP (#9542), and anti-Histone 3 (#4499). Mouse-derived anti-O-Linked N-Acetylglucosamine (RL2) (ab2739) was acquired from Abcam (Cambridge, UK). Mouse anti-α-tubulin (#CP06) was from Merck Millipore (Burlington, MA).
The following chemical compounds were used: OSMI1 compound was kindly provided by Professor Suzanne Walker (Harvard Medical School). Additional OSMI1 compound was purchased from Sigma Aldrich (SML1621). Efficacy of the two OSMI1 stocks was determined to be similar (data not shown); O-GlcNAcase inhibitor PUGNAc (A7229), MG132 proteasome inhibitor (M7449), mTORC1 inhibitor Everolimus (Ev) (SML2282) and PR inhibitor mifepristone (MF) (M8046), were purchased from Sigma Aldrich. γ-secretase inhibitor (GSI) RO4929097 was purchased from Selleckchem (S1575).
Generation of survival plots. Survival plots were generated using the online KM-plotter resource 24 . ER and PR expression were specified to separate the patient groups of interest. Systemically untreated patients were excluded from analysis.
Results
Hormone receptor-negative breast cancer cells are sensitive to OGT inhibition. Importance of OGT in breast cancer has been previously reported, however the diversity and molecular heterogeneity of breast cancer has never been taken into account. Here we compare the impact of OGT inhibition on a panel of breast cancer cells with a different hormone receptor status: ER-and PR-positive MCF7 and T47D; and receptor-negative MDA-MB-231, BT-549, MDA-MB-468, HCC38 and HCC70. In line with the previous reports, the OGT inhibitor, OSMI1 25 , caused a decrease in total protein O-GlcNAcylation ( Fig. 1A ). Treatment caused a consistent 30-60% decrease in total O-GlcNAcylation in all of the tested cell lines, and the response did not depend on the hormone receptor status.
After confirming that OSMI1 is able to inhibit OGT activity, we moved on to assess the effect of OGT inhibition on cell viability. OSMI1 strongly decreased the viability in all TNBC cell lines, with an average EC 20 value of ~7 µM ( Fig. 1B,C ). The strongest effect was observed in the MDA-MB-231 cell line, where treatment with 40 µM OSMI1 led to a complete loss of viability. Notably, the effect on the receptor-positive cell lines MCF7 and T47D, was less prominent, with the average EC 20 value more than two times higher than in the TNBC cells, ~18 µM. Both the OGT knock-down and the treatment with OSMI1 altered cell morphology ( Fig. 1D ,E), indicating possible cell death in MDA-MB-231 and BT-549 cells, but not in the receptor-positive MCF7 and T47D cells. In order to test if the cell death was triggered in response to OGT inhibition, we measured apoptosis in the MDA-MB-231 cells using TUNEL assay following a transient OGT knock-down. Indeed, we found a time-dependent induction of apoptosis ( Fig. 1F ). TUNEL assay detects DNA strand breaks that occur during apoptosis, however the DNA strand breaks can in some cases be repaired 26 . Therefore, we detected total length and cleaved PARP in order to corroborate the induction of apoptosis 27 . Both of the OGT-targeting siRNAs induced PARP cleavage, thereby confirming apoptosis in response to the OGT knockdown ( Supplementary Fig. S1A ).
Cell toxicity caused by the OGT inhibition was more prominent in the TNBC cells, while the effect on the receptor-positive MCF7 and T47D cells was much less pronounced. These data suggest that the hormone receptor status appears to be a strong determinant of sensitivity to OGT inhibition.
Progesterone receptor inhibitor sensitizes hormone receptor-positive cells to OSMI1. Focusing
on the difference in the hormone receptor status between the cell lines, we set out to test if the hormone receptor inhibitors may be used to sensitize receptor-positive cells to OGT inhibition. First, we evaluated the effect of an ER inhibitor, tamoxifen, alone or in combination with OSMI1 on the viability of MCF7 cells. Tamoxifen modestly sensitized cells to OSMI1 ( Fig. 2A ), however the overall loss of cell viability was mild.
Next, we examined the combined effect of PR inhibitor, MF 28 with OSMI1. A combination of MF with OSMI1 led to an 80% decrease of cell viability (Fig. 2B ). We confirmed that MF similarly sensitized another hormone receptor-positive cell line, T47D to OSMI1 (Fig. 2C ). As expected, we did not observe an enhanced effect in the TNBC cell lines ( Supplementary Fig. S1B ).
OGT inhibition resulted in activation of cell death in MDA-MB-231 cells ( Fig. 1F , Supplementary Fig. S1A ). This prompted us to test if MF is able to enhance cell death induction by OSMI1 in the receptor-positive cells. Using Annexin V flow-cytometry assay, we found that the combination of OSMI1 with MF induced prominent cell death ( Fig. 2D ), as well as severe morphological changes indicative of cell death in MCF7 cells ( Supplementary  Fig. S1C ). We noted an accumulation of propidium iodide -positive cells, which represents either cells going through late-stage apoptosis or necrosis 29 . We evaluated whether the cell death occurs through apoptosis or necrosis by using PARP cleavage-signature as a marker for these 27, 30 . OSMI1-MF combination induced prominent accumulation of PARP fragments of 90 and 25 kDa ( Fig. 2E ), which are indicative of apoptosis. However, we did not observe accumulation of PARP cleavage fragments typical for necrosis. Based on these data, inhibition of PR sensitizes receptor-positive BC cells to OSMI1.
Next, we sought to understand the mechanism of this combined effect. PR has been shown to protect breast cancer cells from the radiation-induced cell death 31 , while OGT is known to suppress expansion of the DNA damage signaling 15 . These studies led us to hypothesize that the combined inhibition of OGT and PR results in DNA damage. To test this, we evaluated the induction of the canonical DNA damage marker γ-H2AX 32 . Indeed, OSMI1 significantly potentiated the DNA-damage induced by MF alone (Fig. 2E,F ).
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OGT inhibition causes cell cycle arrest in breast cancer cells. To better understand the consequences
of OGT inhibition in breast cancer cells, we compared the immediate effects on the proteome of the TNBC cells (MDA-MB-231) and the receptor-positive cells (MCF7). Both cell lines were treated with 20 µM OSMI1 for 24 hours, or OGT siRNAs for 72 hours. Following the treatment, proteins were extracted and analyzed with an RPPA assay. To understand the high sensitivity of MDA-MB-231 cells to OGT inhibition, we selected the most up-and down-regulated proteins in this cell line, evaluating the relative changes in protein expression after treatment with OSMI1 ( Fig. 3A ) and the OGT knock-down ( Supplementary Fig. S2A ). The most down-regulated protein was the phosphorylated ribosomal protein S6 (p-PS6). The functional role of PS6 phosphorylation remains a matter of debate, but it has been implicated in the regulation of cell size and glucose homeostasis 33 . We confirmed www.nature.com/scientificreports www.nature.com/scientificreports/ that as the total O-GlcNAcylation decreases after treatment with OSMI1, the p-PS6 is strongly down-regulated in MDA-MB-231, but not in MCF7 (Fig. 3B ). This effect is present as early as 16 hours following the treatment and results in a complete loss of p-PS6 after 48 hours ( Fig. 3C ).
PS6 is phosphorylated in response to activation of the mammalian target of rapamycin complex 1 (mTORC1) 34 . To test whether PS6 phosphorylation mediates the cytotoxic response to OSMI1 treatment in the TNBC cells, we attempted to inhibit mTORC1 to sensitize the MCF7 cells to OGT inhibition. We treated both cell lines with OSMI1 alone and in combination with an mTORC1 inhibitor, Everolimus (Ev). mTORC1 inhibition strongly decreased the viability of the MCF7 cells, however, no combined effect of the dual treatment with OSMI1 was present ( Fig. 3D ). www.nature.com/scientificreports www.nature.com/scientificreports/ In order to identify the pathways that control the increased sensitivity of MDA-MB-231 cells to OGT inhibition, we submitted the list of proteins most differentially regulated by treatment with OSMI1, for the STRING pathway enrichment analysis 35 . Regulation of the mitotic cell cycle was identified as the most affected pathway ( Supplementary Fig. S2B,D) . We evaluated changes in the cell cycle distribution following OGT inhibition with OSMI1 using flow-cytometry. There was a significant increase in the number of cells in G1/G0 phase, along with a decrease in the number of cells in the S phase. Notably, OSMI1 equally impacted cell cycle phase distribution in both the MDA-MB-231 and the MCF7 cell lines (Fig. 3E,F) .
In conclusion, we identified changes in the cell cycle as a major response to OGT inhibition. However, treatment with OSMI1 caused cell cycle arrest in both hormone receptor-negative and -positive cells. This response can therefore not explain the higher sensitivity of TNBC cells to OGT inhibition, indicating that other factors contribute to the differential response. www.nature.com/scientificreports www.nature.com/scientificreports/
Regulation of HES1 in triple-negative breast cancer cells. Searching for potential mediators of high
sensitivity of the TNBC cells to OGT inhibition, we identified transcriptional repressor HES1, as a protein that was strongly decreased in TNBC, but not in the receptor-positive cells (Fig. 3A) . In the RPPA data, HES1 was down-regulated by 30% in MDA-MB-231 following both the treatment with OSMI1 and the OGT knock-down. In MCF7, however, HES1 was mildly increased after treatment with OSMI1 and slightly down-regulated after the OGT knock-down ( Fig. 3A, Supplementary Fig. S2A ). We confirmed that both OSMI1 and OGT knock-down caused a greater than 50% decrease in HES1 protein expression in the TNBC cells, while HES1 expression in the receptor-positive cells remained unchanged, or modestly elevated (Fig. 4A,B ). In addition, HES1 was prominently down-regulated in all tested TNBC cell lines following 24 hours of treatment with OSMI1 ( Supplementary  Fig. S3B ). To confirm the link between HES1 and OGT, we evaluated gene expression of the phosphatase and tensin homolog (PTEN). PTEN expression is known to be negatively regulated by HES1 36 . In accordance with this, both the OGT knockdown and treatment with OSMI1 increased PTEN expression ( Supplementary Fig. S3A ). To our knowledge, this is the first instance where OGT has been shown to regulate PTEN.
In order to determine how inhibition of OGT causes down-regulation of HES1 in TNBC cells, we tested whether HES1 is modified with O-GlcNAc, using immuno-precipitation and confocal microscopy, but did not observe evidence of this (data not shown). Next, we assessed if inhibition of OGT affects transcriptional regulation of HES1, however, it did not affect HES1 mRNA levels ( Supplementary Fig. S3A ). HES1 is an unstable protein, with a half-life of ~2 hours, undergoing continuous proteasomal degradation at the end of this period 37 . It has been reported that OGT inhibits proteasomal activity 38 , which prompted us to suggest that OSMI1 induces proteasomal degradation of HES1. Indeed, inhibition of the proteasome activity with MG-132 completely prevented down-regulation of HES1 in response to OSMI1 (Fig. 4C ). This confirmed that OGT regulates HES1 protein stability through proteasomal degradation, enabling constitutive expression of this transcription factor.
Earlier we found that the combined cytotoxicity of OSMI1 and PR inhibitor was associated with a prominent increase in DNA damage ( Fig. 2E,F) . Inhibition of OGT enhanced the severity of DNA damage induced by MF in MCF7 cells. HES1 interacts with the fanconi anemia core complex, which facilitates the repair of DNA crosslinks 39 . We therefore hypothesized that inhibition of HES1 activity could promote DNA damage. HES1 expression is regulated by Notch signaling. Ligand-activated cleavage of Notch receptors by γ-secretase, and the following activation of down-stream signaling, can be blocked by γ-secretase inhibitor (GSI) 40 . Treatment with GSI alone or a knock-down of HES1 induced mild DNA damage, however, it was greatly potentiated by the simultaneous knock-down of OGT or treatment with OSMI1, respectively. In both cases the combined treatment resulted in a complete loss of HES1 ( Supplementary Fig. S3E ).
Next, we moved on to assess whether targeting HES1 can replicate the cytotoxic effects observed after OGT inhibition. In the MDA-MB-231 cells, knock-down of HES1 potently induced apoptosis (Fig. 5B ). To confirm that this response is not only specific to MDA-MB-231, we performed HES1 knock-downs in two additional TNBC cells lines, BT549 and MDA-MB-468, as well as in the MCF7 cells. Based on visual inspection, we observed fewer cells in response to the HES1 knock-down and possible induction of cell death (Fig. 5A) . Indeed, the knock-down of HES1 induced PARP cleavage in all of the breast cancer cell lines tested (Fig. 5C ). In addition, www.nature.com/scientificreports www.nature.com/scientificreports/ HES1 knockdown sensitized MCF7 cells to OSMI1 ( Supplementary Fig. S3C,D) . Taken together, these results suggest that HES1 is important for proliferation of both TNBC and receptor-positive cell lines.
In breast cancer, HES1 has been implicated in epithelial-to-mesenchymal transition 41 , stimulation of invasion 42 and resistance to HER2 inhibitors 43 . In addition, HES1 has been shown to be important for proliferation of the TNBC cells 42 , which encouraged us to test if HES1 can be used as a prognostic marker. In patients with receptor-positive breast cancer, high level of HES1 expression correlates with longer relapse-free survival www.nature.com/scientificreports www.nature.com/scientificreports/ (Fig. 5D ). In the receptor-negative breast cancers, however, high expression of HES1 was strongly associated with poor prognosis (Fig. 5E ). Based on these data, we propose that HES1 has a distinct function in TNBC and in the hormone receptor-positive cells.
Discussion
Abnormally high levels of O-GlcNAcylation in breast cancer have been linked to sustained proliferation 18 , invasion and metastasis 13 . However, these studies do not account for the characteristic diversity and heterogeneity of breast cancers. Here we found that OGT inhibition or knock-down is significantly more toxic to TNBC cells than to the hormone receptor-positive cells (Fig. 1C) . While it is possible to sensitize receptor-positive cells to OGT inhibition by co-targeting either ER or PR, the combined effect of hormone receptor and OGT inhibition falls short of the prominent cyto-toxicity observed in the TNBC cells. This suggests that there are multiple contributing factors that dictate sensitivity of breast cancer cells to the decrease of protein O-GlcNAcylation.
Aiming to broaden our understanding of the response to OGT inhibition or knock-down, we performed a protein RPPA assay. Confirming previous reports that link OGT to the regulation of cell cycle (reviewed in 44 ) , we show that cell cycle phase distribution is affected upon OGT inhibition, leading to arrest in G1 phase (Fig. 3E,F) . Notably, these changes were universal for the receptor-positive and -negative cell lines. In addition, we demonstrate that inhibition of OGT blocks the mTORC1 signaling. mTORC1 is a key regulator of protein synthesis, supporting up-regulated rate of translation in cancer tissues 45 . Earlier studies have detailed the cross-talk between OGT and mTORC1 in cancer cells, showing that de-regulation of either pathway has a similar effect on the other one [46] [47] [48] . Here we observed that OGT inhibition leads to a decrease in mTORC1 signaling in the TNBC cells, but not in the hormone receptor-positive MCF7 cells. This was apparent from a decrease in phosphorylation of PS6, indicating that p-PS6 level can serve as a biomarker of response to OGT inhibition in breast cancer cells.
OGT has been shown to limit the DNA damage response and facilitate DNA repair by directly inducing O-GlcNAcylation of H2AX and preventing its phosphorylation at the same site 14, 15 . On its own, inhibition of OGT has led to modest DNA damage in all of the tested cell lines. This was greatly increased by additional treatment with MF in MCF7, and accompanied with prominent apoptosis (Fig. 2D-F ). Here we found that OGT inhibition or knock-down leads to the proteasomal degradation of HES1 in the TNBC cells. Notch1-HES1 signaling is known to prevent DNA damage, while Notch1 inhibition or knock-down leads to accumulation of double-strand breaks after irradiation 49 . This response was shown to rely on HES1 interaction with the fanconi-anemia complex, which facilitates DNA repair 39 . In concert with these studies, simultaneous loss of OGT and HES1 resulted in extensive DNA damage in TNBC cells ( Supplementary Fig. S3E ). Our findings raise a possibility of targeting OGT to increase DNA damage in the TNBC cells.
In conclusion, we have established that OGT inhibition has a differential effect on breast cancer cells of different phenotypes, with TNBC cells having a particularly high sensitivity. We identify the transcriptional repressor HES1 and DNA damage as mediators of the response to OGT inhibition in these cells. The sheer complexity of OGT-mediated signaling makes it a challenging enzyme to study. More comprehensive breast cancer models are required to unravel the response to inhibition of OGT, and determine its usefulness for the treatment of TNBC.
Data Availability
The patient survival datasets analyzed during the current study are available in the KM-plotter repository (http:// kmplot.com/analysis/). The full RPPA results and the confocal microscopy images, showing the lack of O-GlcNAc modification on HES1, are available from the corresponding author on reasonable request. All other data generated or analyzed during this study are included in this published article and its Supplementary Files.
